NCT05485987Phase 2Completed

A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-08-29Actual

Enrollment · participants5Actual

Source updated2025-08-22Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Friedreich Ataxia

Treatments or interventions studied

VatiquinoneDrugAlso known as PTC743, EPI-743

Primary outcomes · main study measures

Read the study measures

measure: Plasma Concentration of Vatiquinone; timeFrame: Pre-morning dose (0 hour) at Week 4; 1 to 3 hours and 3 to 6 hours post-morning dose at Weeks 4, 12, and 24; measure: Area Under the Curve (AUC) of Vatiquinone; timeFrame: Pre-morning dose (0 hour) at Week 4; 1 to 3 hours and 3 to 6 hours post-morning dose at Weeks 4, 12, and 24; measure: Number of Participants With Adverse Events; timeFrame: Baseline up to Week 76

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history